Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Yale University
- Target Recruit Count
- 12
- Registration Number
- NCT06160284
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Psilocybin rTMS for Treatment Resistant Depression
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Texas at Austin
- Target Recruit Count
- 100
- Registration Number
- NCT06132178
- Locations
- 🇺🇸
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas, United States
Safety Profile of Psilocybin for Cocaine Use Disorder
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 10
- Registration Number
- NCT06102434
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 120
- Registration Number
- NCT06081179
- Locations
- 🇨🇭
Psychiatrische Universitätsklinik Zürich, Zürich, Switzerland
A Randomized Neuroimaging Trial of Psilocybin in Depression
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 50
- Registration Number
- NCT06072898
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 90
- Registration Number
- NCT06067737
- Locations
- 🇺🇸
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 60
- Registration Number
- NCT06041152
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 90
- Registration Number
- NCT06005662
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Psilocybin in Cancer Pain Study
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Yvan Beaussant, MD, MSci
- Target Recruit Count
- 15
- Registration Number
- NCT06001749
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 128
- Registration Number
- NCT05995769
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.